BellaSeno
BellaSeno develops absorbable, implantable scaffolds that promote natural tissue regeneration, reducing the need for permanent implants and associated complications.
- CEO / Founder
- Mohit Chhaya
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $4.7M
- Latest Round
- Grant
- Key Investors
- Saxony Development Bank (SAB), European Fund for Regional Development (EFRE), Germany's Federal Ministry of Education and Research (BMBF), Australian government
Technology & Products
Key Products
["Absorbable scaffolds for breast reconstruction","Absorbable scaffolds for soft tissue applications"]
Technological Advantage
Proprietary scaffold formulations that enhance biocompatibility and reduce complications associated with permanent implants.
Differentiation
Value Proposition
Offers biocompatible and biodegradable absorbable scaffolds that integrate with the body's natural tissue to promote regeneration.
How They Differentiate
BellaSeno differentiates itself through its absorbable scaffold technology as opposed to permanent implants, offering a regenerative solution that integrates with natural tissue.
Market & Competition
Target Customers
Medical professionals, hospitals, and patients in need of breast reconstruction or other soft tissue repair procedures
Industry Verticals
["Medical Devices","Tissue Engineering","Regenerative Medicine"]
Competitors
Allergan; Mentor Worldwide LLC
Growth & Milestones
Growth Metrics
Completion of significant clinical trials indicating progress towards commercialization
Major Milestones
["Completion of two significant clinical trials","Positive one-year patient follow-up data for resorbable breast and pectus excavatum scaffolds"]